abstract IL-5 is the most potent activator of eosinophils and is produced by Th2 cells and
ILC2s. A role for IL-5 in eosinophil extracellular trap cell death, ie, a proinflammatory cell …

Chronic rhinosinusitis (CRS) is one of the most frequent comorbidities associated with
asthma and it contributes to an amplified global disease burden in asthmatics. CRS …

Benralizumab is a humanized monoclonal antibody which binds to the α subunit of the
interleukin-5 (IL-5) receptor and to the FcγRIIIa receptor expressed by natural killer cells …

Secondary adrenal insufficiency (AI) occurs as the result of any process that disrupts normal
hypothalamic and/or anterior pituitary function and causes a decrease in the secretion of …

Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and
anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma. While high …

Background Severe asthma is a heterogeneous inflammatory disease driven by eosinophilic
inflammation in the majority of cases. Despite biologic therapy patients may still be sub …

Improved understanding of the contribution of immune-inflammatory mechanisms in allergic
diseases and asthma has encouraged development of biologicals and small molecules …

Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic
asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti …

Severe eosinophilic asthma is a complex disease and much effort has been made to fully
understand its mechanisms. Bronchial remodeling and loss of lung function are important …

Background: Benralizumab has been shown to restore good control of severe eosinophilic
asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years …